Cboe UK CHF

Idorsia Ltd (IDIAZ.XC)

1.6340

+0.0840

+(5.42%)

At close: 2:25:23 PM GMT+1

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

Allschwil, Switzerland – May 28, 2025At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. The meeting was attended by 166 shareholders, representing a total of 97’748’740 shares, or 43.28% of the total outstanding shares. Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update. Jean-Paul Clozel, MD, Chairman of the Board of Directors, c

GlobeNewswire 2 days ago

IDRSF
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability

Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026Holistic convertible debt restructuring progressing with bondholder meeting to be held in the coming weeks – ~90% of bondholders have already agreed to amend the terms and to exchange bonds for newly created notes in Idorsia Investments SARLIdorsia re-activating collaboration discussions for aprocitentan following the removal of the TRYVIO REMS and p

GlobeNewswire 9 days ago

IDRSF
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

Allschwil, Switzerland – May 2, 2025Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2024, will be held on Wednesday, May 28, 2025, at 09.00 CEST at the Congress Center, Messe Basel, Switzerland. Jean-Paul Clozel, Chairman of the Board of Idorsia, commented:“The team at Idorsia continues to go the extra mile to secure the co

GlobeNewswire 28 days ago

IDRSF
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 30, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2025. Business highlights Q1 2025 QUVIVIQ™ (daridorexant): Strong performance and accelerating sales in Q1 2025 with total Idorsia-led net sales of CHF 25 m.QUVIVIQ EUCAN: Demand grew by 50% from Q4 2024 to Q1 2025, strongly driven by reimbursed markets. Overall, more than 10 million nights of sleep prescribed in Q1 2025.Daridore

GlobeNewswire 30 days ago

IDRSF
New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine

Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-morning sleepiness.Daridorexant improved next-morning sleepiness compared to placebo from as early as the first day of treatment.Daridorexant improved daytime ability to function and daytime alertness each week over the 3-month treatment duration. Allschwil, Switzerland – April 29, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of “Effect of daridorexant on nigh

GlobeNewswire last month

IDRSF
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere kantonale Nachlassbehörde) (the Court) in relation to its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, which matured on January 17, 2025, was held yesterday and that the Court approved th

GlobeNewswire last month

IDRSF
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertension1. The publication reports preplanned analyses of the efficacy, tolerability and safety of aprocitentan

GlobeNewswire last month

IDRSF
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the updated label for TRYVIO™ (aprocitentan). TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood pressure in

GlobeNewswire last month

IDRSF
Idorsia publishes its Annual Report 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, Governance Report, Compensation Report, Sustainability Report, and Financial Report (already published on March 4, 2025). All five books of the Annual Report 2024 are available at www.idorsia.com/annual-report. Note to ShareholdersThe Annual General Meeting (AGM) of Shareholders to approve the Annu

GlobeNewswire 2 months ago

IDRSF
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact with the REMS Allschwil, Switzerland – March 17, 2025Idorsia Ltd (SIX: IDIA) today announced that – effective immediately – the US FDA has fully released TRYVIO™ (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement. TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination

GlobeNewswire 2 months ago

IDRSF
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia and nocturiaIn this study, daridorexant was safe and well tolerated, consistent with the well-documented safety profile observed in the Phase 3 studies in chronic insomnia.The data from the Phase 4 study is published in the Journal of Sleep ResearchOn World Sleep Day, Idorsia unites with the World S

GlobeNewswire 2 months ago

IDRSF
Idorsia Ltd (IDRSF) (Q4 2024) Earnings Call Highlights: Strategic Moves and Financial Resilience

Idorsia Ltd (IDRSF) reports significant growth in QUVIVIQ sales and successful debt restructuring, while navigating financial challenges and planning for future expansion.

GuruFocus.com 2 months ago

IDIA.SW
Idorsia announces financial results for 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for 2024. Business highlights 2024 Viatris collaboration: Global research and development collaboration, focused on the development and commercialization of selatogrel and cenerimod entered in March 2024.QUVIVIQ™ (daridorexant): Outstanding launch dynamic in France, and a strong performance in Germany accelerate sales in 2024 – Total Idorsia-led net sales

GlobeNewswire 2 months ago

IDRSF
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call

Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day. Date: Tuesday, March 4, 2025 Time: 14:00 CET / 13:00 GMT / 08:00 EST The call will start with presentations by senior management, followed by a Q&A session. Live Webcast (audio + slides):The live webcast can be accessed from the Idorsia website www.idorsia.com. Dial-in procedure for analysts (audio only):

GlobeNewswire 2 months ago

IDRSF
Idorsia’s Tryvio deal collapses, forcing company to find cash urgently

With a potential buyer not working out, Idorsia has adjusted an existing partnership and restructured bonds to raise cash.

Pharmaceutical Technology 2 months ago

IDIA.SW

VTRS
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations

Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia’s outstanding convertible bond debt – allowing the removal of a large debt overhang and providing CHF 150 million of new fundingAgreement with Viatris to revise collaboration for selatogrel and cenerimod results in the removal of significant cash requirement for 2025Release from exclusivity constraint allows Idorsia to pivot to ne

GlobeNewswire 3 months ago

IDRSF
Idorsia and Viatris update their collaboration for selatogrel and cenerimod

Ad hoc announcement pursuant to Art. 53 LR Idorsia’s contribution to the development costs reduced by USD 100 millionViatris potential regulatory and sales milestones payments to Idorsia reduced by USD 250 million Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for selatogrel and cenerimod. In exchange for a USD 100

GlobeNewswire 3 months ago

IDRSF
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed party for the global rights to aprocitentan has concluded without the party signing the deal as foreseen in the non-binding term sheet. Idorsia will retain the exclusivity fee of USD 35 million paid in December 2024. André C. Muller, CEO of Idorsia, commented:“It is disappointing that the undisclose

GlobeNewswire 3 months ago

IDRSF
Bondholders approve amended terms of the 2025 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR The proposed amendments to the terms of the 2025 convertible bond have been approved by the bondholders and will become binding and effective upon approval by the higher cantonal composition authority. Allschwil, Switzerland – February 25, 2025Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of a bondholders’ meeting held at 17:30 CET on February 25, 2025. The bondholders’ meeting for holders of Idorsia’s outstanding 2025 convertible bonds

GlobeNewswire 3 months ago

IDRSF

Performance Overview

Return	IDIAZ.XC	MSCI WORLD (^990100-USD-STRD)
YTD	+107.76%	+3.36%
1-Year	-30.29%	+12.06%
3-Year	-92.64%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Idorsia Ltd (IDIAZ.XC)

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability

Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset

New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine

Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

Idorsia publishes its Annual Report 2024

US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia

Idorsia Ltd (IDRSF) (Q4 2024) Earnings Call Highlights: Strategic Moves and Financial Resilience

Idorsia announces financial results for 2024

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call

Idorsia’s Tryvio deal collapses, forcing company to find cash urgently

Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations

Idorsia and Viatris update their collaboration for selatogrel and cenerimod

Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties

Bondholders approve amended terms of the 2025 convertible bonds

Performance Overview